These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 22898344)

  • 1. Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and intravitreal biologics for ocular inflammation.
    Yeh S; Albini TA; Moshfeghi AA; Nussenblatt RB
    Am J Ophthalmol; 2012 Sep; 154(3):429-435.e2. PubMed ID: 22898344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.
    Mitchell P
    Curr Med Res Opin; 2011 Jul; 27(7):1465-75. PubMed ID: 21623685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.
    Moja L; Lucenteforte E; Kwag KH; Bertele V; Campomori A; Chakravarthy U; D'Amico R; Dickersin K; Kodjikian L; Lindsley K; Loke Y; Maguire M; Martin DF; Mugelli A; Mühlbauer B; Püntmann I; Reeves B; Rogers C; Schmucker C; Subramanian ML; Virgili G
    Cochrane Database Syst Rev; 2014 Sep; 9(9):CD011230. PubMed ID: 25220133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How the comparison of age-related macular degeneration treatments trial results will impact clinical care.
    Davis J; Olsen TW; Stewart M; Sternberg P
    Am J Ophthalmol; 2011 Oct; 152(4):509-14. PubMed ID: 21961847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to antivascular endothelial growth factor agents: a pilot study from the Pan American Collaborative Retina Study Group.
    Wu L; Arevalo JF; Hernandez-Bogantes E; Regatieri CV; Roca JA; Farah ME
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):366-71. PubMed ID: 23215543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
    Jeganathan VS; Verma N
    Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
    Tolentino M
    Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
    Abouammoh M; Sharma S
    Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.
    Thulliez M; Angoulvant D; Le Lez ML; Jonville-Bera AP; Pisella PJ; Gueyffier F; Bejan-Angoulvant T
    JAMA Ophthalmol; 2014 Nov; 132(11):1317-26. PubMed ID: 25058694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
    Day S; Acquah K; Mruthyunjaya P; Grossman DS; Lee PP; Sloan FA
    Am J Ophthalmol; 2011 Aug; 152(2):266-72. PubMed ID: 21664593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks.
    Prescrire Int; 2015 Sep; 24(163):201-4. PubMed ID: 26417625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab for neovascular ocular diseases.
    Lynch SS; Cheng CM
    Ann Pharmacother; 2007 Apr; 41(4):614-25. PubMed ID: 17355998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials.
    Ueta T; Noda Y; Toyama T; Yamaguchi T; Amano S
    Ophthalmology; 2014 Nov; 121(11):2193-203.e1-7. PubMed ID: 25023760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
    Małgorzata F
    Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
    Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
    Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of the comparisons of age-related macular degeneration treatments trials on clinical practice: what have we learned?
    Do DV
    Ophthalmology; 2013 May; 120(5 Suppl):S8-10. PubMed ID: 23642785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review.
    Schmucker C; Loke YK; Ehlken C; Agostini HT; Hansen LL; Antes G; Lelgemann M
    Br J Ophthalmol; 2011 Mar; 95(3):308-17. PubMed ID: 20971791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
    El-Mollayess GM; Noureddine BN; Bashshur ZF
    Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic efficacy of bevacizumab for age-related macular degeneration: what are the implications of CATT for routine management?
    Ziemssen F; Sobolewska B
    Drugs Aging; 2011 Nov; 28(11):853-65. PubMed ID: 21970950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.